ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results

被引：0
|
作者：
Strober, Bruce [1 ]
Crowley, Jeffrey [2 ]
Valdes, Joaquin [3 ]
Gu, Yihua [3 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Bakersfield Dermatol, Bakersfield, CA USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2011年 / 64卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB155 / AB155
页数：1
相关论文
共 50 条
  • [31] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
    Bachelez, Herve
    van de Kerkhof, Peter C. M.
    Strohal, Robert
    Kubanov, Alexey
    Valenzuela, Fernando
    Lee, Joo-Heung
    Yakusevich, Vladimir
    Chimenti, Sergio
    Papacharalambous, Jocelyne
    Proulx, James
    Gupta, Pankaj
    Tan, Huaming
    Tawadrous, Margaret
    Valdez, Hernan
    Wolk, Robert
    LANCET, 2015, 386 (9993): : 552 - 561
  • [32] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [33] Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
    Reich, Kristian
    Soung, Jennifer
    Gooderham, Melinda
    Zhang, Zuoshun
    Nograles, Kristine
    Day, Robert M.
    Ferris, Laura
    Goodfield, Mark
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
    Mostafa, N. M.
    Nader, A. M.
    Noertersheuser, P.
    Okun, M.
    Awni, W. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 490 - 497
  • [35] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [36] Efficacy and safety profiles of etanercept 50 mg twice weekly for up to 144 weeks in patients with moderate to severe plaque psoriasis
    Tyring, Stephen
    Langley, Richard
    Gordon, Kenneth
    Poulin, Yves
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB182 - AB182
  • [37] COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS ETANERCEPT USING EFFICACY RESULTS FROM PIVOTAL CLINICAL TRIALS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Teeple, A.
    Muser, E.
    VALUE IN HEALTH, 2018, 21 : S241 - S241
  • [38] The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Menter, A
    Cather, JC
    Baker, D
    Farber, HF
    Lebwohl, M
    Darif, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (01) : 61 - 63
  • [39] Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial
    Kimball, Alexa
    Zhong, Jianhua
    Valdes, Joaquin
    Gordon, Kenneth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB168 - AB168
  • [40] Pooled safety and efficacy results from two phase III trials comparing briakinumab with etanercept and placebo for the treatment of moderate to severe psoriasis
    Strober, Bruce
    Gottlieb, Alice
    Williams, David
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB146 - AB146
12345